{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:36:14Z","timestamp":1760747774712,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejca.2020.11.023","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T06:24:18Z","timestamp":1609395858000},"page":"351-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-9322","authenticated-orcid":false,"given":"Arlindo","family":"R. Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0606-8017","authenticated-orcid":false,"given":"Sofia","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-7256","authenticated-orcid":false,"given":"Samuel","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-0407","authenticated-orcid":false,"given":"Noam","family":"Ponde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.11.023_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.11.023_bib2","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1002\/cncr.31657","article-title":"Optimal treatment of early stage HER2-positive breast cancer","volume":"124","author":"Pernas","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.11.023_bib3","doi-asserted-by":"crossref","first-page":"102033","DOI":"10.1016\/j.ctrv.2020.102033","article-title":"HER2-positive advanced breast cancer treatment in 2020","author":"Cesca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2020.11.023_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer","volume":"377","author":"Von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.023_bib6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1517\/14740338.2016.1167185","article-title":"Pertuzumab for the treatment of breast cancer: a safety review","volume":"15","author":"Gao","year":"2016","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.ejca.2020.11.023_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.023_bib9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1634\/theoncologist.12-12-1443","article-title":"Review: side effects of approved molecular targeted therapies in solid cancers","volume":"12","author":"Widakowich","year":"2007","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib10","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1007\/s13277-013-1533-1","article-title":"Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis","volume":"35","author":"Li","year":"2014","journal-title":"Tumor Biol"},{"key":"10.1016\/j.ejca.2020.11.023_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/annonc\/mdw695","article-title":"Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab","volume":"28","author":"Swain","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.598","article-title":"Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel","volume":"33","author":"Miles","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib13","doi-asserted-by":"crossref","first-page":"djw037","DOI":"10.1093\/jnci\/djw037","article-title":"Lapatinib-related rash and breast cancer outcome in the ALTTO phase III randomized trial","volume":"108","author":"Sonnenblick","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.11.023_bib14","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2013.50.9448","article-title":"Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial","volume":"31","author":"Azim","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.023_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S1470-2045(20)30058-9","article-title":"Is HER2-positive metastatic breast cancer still an incurable disease?","volume":"21","author":"Lambertini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib17","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","article-title":"Biomarker Analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer","volume":"32","author":"Baselga","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib18","article-title":"HER2-Enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade","author":"Prat","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.11.023_bib19","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","article-title":"Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases","volume":"30","author":"Medina","year":"2008","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.ejca.2020.11.023_bib20","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1158\/1535-7163.MCT-09-0291","article-title":"Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization","volume":"8","author":"Hughes","year":"2009","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.ejca.2020.11.023_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0896-6273(02)01128-5","article-title":"Colonic epithelial expression of erbB2 is required for postnatal maintenance of the enteric nervous system","volume":"37","author":"Crone","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.ejca.2020.11.023_bib22","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1158\/1535-7163.MCT-17-1268","article-title":"Mechanistic investigations of diarrhea toxicity induced by Anti-HER2\/3 combination therapy","volume":"17","author":"Moisan","year":"2018","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.ejca.2020.11.023_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1758834009355164","article-title":"Review: chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management","volume":"2","author":"Stein","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2020.11.023_bib24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2009.24.1661","article-title":"Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2\u2013negative metastat","volume":"28","author":"Gianni","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:56Z","timestamp":1760733236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":24,"alternative-id":["S0959804920313605"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}